[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Dundee\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":100},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100637855","better-tests--improving-diagnostic-accuracy-and-prognostication-in-interstitial-lung-diseases-100637855",false,"NCT07615504","Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases","Better Tests","Inclusion Criteria:\n\nTo participate subjects will either have to be active Pigeon Fanciers, or will be either attending ILD clinics for management of their interstitial lung disease or will present acutely to hospital services with severe respiratory failure due to ILD.\n\nExclusion Criteria:\n\nUnable to provide informed consent",true,"ALL","18 Years","90 Years",{"count":21,"type":22},750,"ESTIMATED","5 Years","OBSERVATIONAL","Patients with interstitial lung diseases (ILD) suffer significant delays in obtaining a diagnosis, and objective evidence of support for immunosuppressive therapies, due to weaknesses in the diagnostic tests available in ILD clinics.\n\nThis project will assess several non-invasive assessments, focusing on blood and breath based sampling, to identify candidate tests that may translate through to routine clinical use. The tests being assessed will be initially employed in Pigeon Fanciers, a group recognised to be at high risk of developing ILD compared to age matched controls, due to their regular exposure to a known cause of ILD. Candidate tests will also be assessed for change over time in this group. Tests which show promise will then be utilised in patients with ILD diagnoses, including those with severe respiratory failure, to assess their acceptability to patients and their ability to provide useful prognostic information, to allow powering of future definitive clinical trials.",[27],"Interstitial Lung Disease (ILD)",[29,30,31,32,33,34],"Interstitial Lung Disease","Lung fibrosis","Non-invasive assessment","Pigeon fanciers","Prognostication","Diagnosis","RECRUITING","2026-05-22",{"date":38,"type":39},"2026-05-29","ACTUAL",{"date":41,"type":39},"2026-01-17",{"date":43,"type":22},"2036-01-15",{"name":45,"class":46},"University of Dundee","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100549525","phase-2-sotagliflozin-in-patients-with-heart-failure-symptoms-and-type-1-diabetes-100549525","NCT06435156","Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes","A Phase 2 Double-blind Randomised Controlled Trial Studying the Effect of Sotagliflozin Versus Placebo in Individuals With Heart Failure and Type 1 Diabetes.","SOPHIST","Inclusion Criteria:\n\n1. Age 18 years to \\\u003C85 years.\n2. Type 1 diabetes.\n3. Insulin dose ≥0.5 units\u002Fkg body weight at screening or BMI ≥25kg\u002Fm2 at screening\n4. Using continuous glucose monitor at screening or willing to use one for the duration of the trial.\n5. Diagnosis of heart failure (HF) or high-risk for HF, defined as any of the following:\n\n   NT-proBNP ≥250ng\u002FL for those in atrial fibrillation\u002Fflutter, ≥125 ng\u002FL for those in all other rhythms or\n\n   Previous HF hospitalisation where HF was documented as the primary cause of hospitalisation and there was a requirement for loop diuretics or Impaired left ventricular (LV) function (i.e. LVEF \\\u003C50% by any imaging modality) at any time or Preserved LV systolic function (LVEF ≥50%) with left atrial enlargement (2-dimensional measurement of left atrial width ≥3.8cm or left atrial length ≥5.0 cm or left atrial area ≥20cm2 or left atrial volume index \\>29 ml\u002Fm2) within the last 24 months.\n\n   or Preserved LV systolic function (LVEF ≥50%) with left ventricular hypertrophy (2-dimensional measurement of end-diastolic interventricular septal diameter ≥1.2cm or end-diastolic left ventricular posterior wall diameter ≥1.2cm) within the last 24 months.\n\n   or Preserved LV systolic function (LVEF ≥50%) with diastolic dysfunction (septal e' \\\u003C7cm\u002Fsec or lateral e' \\\u003C10cm\u002Fsec or average E\u002Fe' ≥15) within the last 24 months.\n6. New York Heart Association Class II-IV at screening.\n7. Kansas City Cardiomyopathy clinical summary score \\\u003C85 at screening.\n\nExclusion Criteria:\n\n1. Cardiac surgery (coronary artery bypass graft or valve replacement), type 1 myocardial infarction, implantation of cardiac device (including biventricular pacemaker) or cardiac mechanical support implantation within 1 month of screening, or between screening and randomisation, or planned during the trial.\n2. End-stage heart failure requiring left ventricular assist devices, intra-aortic balloon pump, or any type of mechanical support at the time of randomisation.\n3. Documented primary severe valvular heart disease, amyloidosis or hypertrophic cardiomyopathy as principal cause of heart failure as judged by the local investigator.\n4. Respiratory disease thought to be the primary cause of dyspnoea as assessed by the local investigator.\n5. Chronic kidney disease with estimated glomerular filtration rate \\\u003C25ml\u002Fmin\u002F1.73m2 at screening.\n6. Moderate or severe hepatic impairment (e.g. Child-Pugh B and C) at screening as judged by the local investigator.\n7. Use of sotagliflozin or any SGLT2 inhibitor within 1 month of screening or between screening and randomisation.\n8. Previous hypersensitivity\u002Fintolerance to SGLT2 inhibitors.\n9. Presence of malignancy with expected life expectancy \\\u003C1 year at screening.\n10. Severe hypoglycaemia (hospitalisation for hypoglycaemia or episode requiring external assistance to treat) within 1 month prior to screening or between screening and randomisation.\n11. One episode of diabetic ketoacidosis or nonketotic hyperosmolar state within 1 month of screening or between screening and randomisation, or ≥2 diabetic ketoacidosis or nonketotic hyperosmolar state events within 6 months of screening.\n12. Pregnant or lactating women.\n13. Women of childbearing age or male partners of women of childbearing age and not practicing an acceptable method of birth control, see section 8.11\n14. On a ketogenic diet.\n15. Unwilling\u002Funable to share glucose and ketone monitoring data.\n16. Use of any investigational drugs within five times of the elimination half-life after the last dose or within 30 days, whichever is longer. Current enrolment in non-interventional, observational studies will be allowed.","84 Years",{"count":57,"type":22},320,"INTERVENTIONAL",[60],"PHASE2","People with type 1 diabetes sometimes develop heart failure which can cause symptoms like breathlessness, tiredness or ankle swelling, reduced quality of life and lead to being admitted to hospital or suffering potential fatal consequences. This trial is investigating if a tablet called sotagliflozin, can improve quality of life in people with type 1 diabetes and heart failure. In addition, this trial will also assess the safety and tolerability of sotagliflozin in this population.\n\nIn previous trials that included people with type 2 diabetes and heart failure sotagliflozin was shown to improve patients' symptoms of heart failure, quality of life and reduce the chance of people with heart failure being admitted to hospital or dying. However, people with type 1 diabetes and heart failure were not included in these trials meaning that it is not known if these benefits also apply to this population.\n\nThis trial aims to recruit 320 people with type 1 diabetes and heart failure symptoms in multiple sites in the United Kingdom (UK). This trial will compare the health and quality of life of participants who take sotagliflozin tablets with participants who take placebo tablets, which is a dummy tablet that looks the same as sotagliflozin. Participants will be randomly allocated to one of two groups (i.e. one taking sotagliflozin and the other the placebo) and both the medical team and participants will not know in which group each participant is until the end of the study. Participants will be in the trial for approximately 6 months and will be given sotagliflozin or placebo tablets to take 1 per day for 4 months. The trial is expected to run for a total of 26 months.",[63,64],"Type 1 Diabetes","Heart Failure",[63,66,67,68],"heart failure","Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors","sotagliflozin","2026-03-31",{"date":71,"type":39},"2026-04-06",{"date":73,"type":39},"2025-01-28",{"date":75,"type":22},"2027-10-31",{"name":45,"class":46},17,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100346465","the-bridge-study---bronchiectasis-research-involving-databases-genomics-and-endotyping-100346465","NCT03791086","The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping","The BRIDGE Study - Bronchiectasis Research Involving Databases, Genomics and Endotyping. An EMBARC2 and EMBARC3 Study","BRIDGE","Inclusion Criteria:\n\n* A previous CT scan showing bronchiectasis along with compatible clinical syndrome of cough, sputum production and\u002For recurrent respiratory tract infections.\n* A primary diagnosis of bronchiectasis made by a respiratory physician\n* At the screening visit the individual will have been clinically stable for 4 weeks indicated by the lack of any treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks.\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* \\\u003C18years of age\n* Patients with active tuberculosis\n* Treatment with antibiotics or corticosteroids for a pulmonary exacerbation in the previous 4 weeks\n* Bronchiectasis due to cystic fibrosis",{"count":87,"type":22},1000,"Bronchiectasis is a complex heterogeneous disorder. Treatment is challenging and many recent randomized controlled trials have been negative. It is believed that bronchiectasis as a broad diagnosis incorporates multiple different patient subgroups (also known as phenotypes) and molecular entities (referred to as endotypes). This study aims to phenotype and endotype bronchiectasis during stable disease and exacerbations, to develop strategies for personalised medicine.\n\nPrimary Objective To determine molecular endotypes of bronchiectasis which can guide response to treatment.\n\nSecondary Objectives\n\n1. To determine molecular endotypes of stable bronchiectasis\n2. To determine the causes and inflammatory profiles of bronchiectasis exacerbations\n3. To validate candidate biomarkers of stable and exacerbation endotypes to use in stratified medicine\n4. To perform in-vivo or in-vitro proof of concept studies using phenotypic data to identify patient populations likely to benefit in future randomized controlled trials\n\nThis is an observational cohort study that will aim to identify patient subgroups and link these with meaningful clinical outcomes.",[90],"Bronchiectasis Adult","2023-03-19",{"date":93,"type":39},"2023-03-22",{"date":95,"type":39},"2019-11-01",{"date":97,"type":22},"2027-02-01",{"name":45,"class":46},1,""]